Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Open access
Gregson, John, Tang, Michele, Ndembi, Nicaise, Hamers, Raph L, Rhee, Soo-Yon, Marconi, Vincent C, Diero, Lameck, Brooks, Katherine A, Theys, Kristof, Rinke de Wit, Tobias, Arruda, Monica, Garcia, Frederico, Monge, Susana, Günthard, Huldrych F, Hoffmann, Christopher J, Kanki, Phyllis J, Kumarasamy, Nagalingeshwaran, Kerschberger, Bernard, Mor, Orna, Charpentier, Charlotte, Todesco, Eva, Rokx, Casper, Gras, Luuk, Helvas, Elias K, Sunpath, Henry, Di Carlo, Domenico, Antinori, Antonio, Andreoni, Massimo, Latini, Alessandra, Mussini, Cristina, Aghokeng, Avelin, Sonnerborg, Anders, Neogi, Ujjwal, Fessel, William J, Agolory, Simon, Yang, Chunfu, Blanco, Jose L, Juma, James M, Smit, Erasmus, Schmidt, Daniel, Watera, Christine, Asio, Juliet, Kurungi, Wilford, Tostevin, Anna, El-Hay, Tal, Clumeck, Nathan, Goedhals, Dominique, Van Vuuren, Cloete, Bester, Philip A, Sabin, Caroline, Mukui, Irene, Santoro, MARIA M, Perno, Carlo F, Hunt, Gillian, Morris, Lynn, Camacho, Ricardo, De Oliveira, Tulio, Pillay, Deenan, Schulter, Eugene, Murakami-Ogasawara, Akio, Reyes-Terán, Gustavo, Romero, Karla, Avila-Rios, Santiago, Sirivichayakul, Sunee, Ruxrungtham, Kiat, Mekprasan, Suwanna, Dunn, David, Kaleebu, Pontiano, Raizes, Elliot, Kantor, Rami, Shafer, Robert W, Gupta, Ravindra K·2016·The Lancet Infectious Diseases

Abstract

BACKGROUND: Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. METHODS: The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. FINDINGS: We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27-1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20-1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]). INTERPRETATION: We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial. FUNDING: The Wellcome Trust.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(15)00536-8

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 267

Metadata

Authors
Gregson, J., Tang, M., Ndembi, N., Hamers, R. L., Rhee, S.-Y., Marconi, V. C., Diero, L., Brooks, K. A., Theys, K., Rinke de Wit, T., Arruda, M., Garcia, F., Monge, S., Günthard, H. F., Hoffmann, C. J., Kanki, P. J., Kumarasamy, N., Kerschberger, B., Mor, O., Charpentier, C., Todesco, E., Rokx, C., Gras, L., Helvas, E. K., Sunpath, H., Di Carlo, D., Antinori, A., Andreoni, M., Latini, A., Mussini, C., Aghokeng, A., Sonnerborg, A., Neogi, U., Fessel, W. J., Agolory, S., Yang, C., Blanco, J. L., Juma, J. M., Smit, E., Schmidt, D., Watera, C., Asio, J., Kurungi, W., Tostevin, A., El-Hay, T., Clumeck, N., Goedhals, D., Van Vuuren, C., Bester, P. A., Sabin, C., Mukui, I., Santoro, M. M., Perno, C. F., Hunt, G., Morris, L., Camacho, R., De Oliveira, T., Pillay, D., Schulter, E., Murakami-Ogasawara, A., Reyes-Terán, G., Romero, K., Avila-Rios, S., Sirivichayakul, S., Ruxrungtham, K., Mekprasan, S., Dunn, D., Kaleebu, P., Raizes, E., Kantor, R., Shafer, R. W., & Gupta, R. K.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2016-05
Volume
16
Issue
5
Pages
565-575
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2462213043
Cited by
267
References
1
FWCI
33.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. https://app.cochat.ai/papers/10.1016/s1473-3099(15)00536-8
The paper
Gregson, J., Tang, M., Ndembi, N., Hamers, R. L., Rhee, S.-Y., Marconi, V. C., Diero, L., Brooks, K. A., Theys, K., Rinke de Wit, T., Arruda, M., Garcia, F., Monge, S., Günthard, H. F., Hoffmann, C. J., Kanki, P. J., Kumarasamy, N., Kerschberger, B., Mor, O., . . . Gupta, R. K. (2016). Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(15)00536-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.